Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 11, 2011, Pages 2097-2104

  Karmali, Reem ^a   Larson, Melissa L ^a   Wooldridge, James E ^b   Gregory, Stephanie A ^a   O'Brien, Teresa ^a   Shammo, Jamile M ^a   Bueschel, Katherine ^a   Venugopal, Parameswaran ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Chemoimmunotherapy; Diffuse large B cell lymphoma; GM CSF; Immune priming; Immunomodulation; Mantle cell lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBOLISM; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GRANULOCYTOPENIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HUMAN; IMMUNOSTIMULATION; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; LARGE CELL LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM HEMORRHAGE; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; WEAKNESS;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEUTROPENIA; PILOT PROJECTS; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 80054985322     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.589549     Document Type: Article

References (52)

1. American Cancer Society. Cancer facts and figures 2010. Atlanta, GA: ACS. 2010. Available from: http://www.cancer.org/acs/groups/content/@nho/documents/ document/acspc-024113.pdf
2. The Non-Hodgkin 's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin 's lymphoma. Blood 1997;89: 3909-3918.
3. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin 's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin 's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.
4. The Non-Hodgkin 's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin 's lymphoma patients. Ann Oncol 1997;8:973-978.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
6. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
7. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabTh era International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
8. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 to R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol 2009;27(Suppl.): Abstract 8506.
9. Zinzani PL, Rossi G, Franceschetti S, et al. Phase II trial of shortcourse R-CHOP followed by 90 Y-ibritumomab tiuxetan in previously untreated high risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010;16:3998-4004.
10. Karmali R, Manson A, Venugopal P, et al. Phase II study of 2-weekly CHOP+rituximab followed by yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): final analysis. Blood 2010;116(Suppl. 1): Abstract 3947.
11. Coiffier B. Standard treatment of advanced-stage diffuse large B-cell lymphoma. Semin Hematol 2006;43:213-220.
12. Coiffier B. Treatment of non-Hodgkin 's lymphoma: a look over the past decade. Clin Lymphoma Myeloma 2006;7(Suppl. 1):S7-S13.
13. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005;23:1984-1992.
14. Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000;39:77-85.
15. Romaguera JE, Fayad L, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and witout stem-cell transplantation in patient with untreated aggressive mantle-cell lymphoma. Br J Haem 2010;150:200-208.
16. Kahl B, Li H, Smith MR, et al. The VcR-CVAD regimen produces high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405-a phase II study of VcR-CVAD with maintenance rituximab for MCL. Blood 2009;114(Suppl. 1): Abstract 1661.
17. Rummel ML, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect to progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment for patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009;114(Suppl. 1): Abstract 405.
18. Geisler C. Front-line treatment of mantle cell lymphoma. Haematologica 2010;95:1241-1243.
19. Balducci L, Carreca I. The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 2002;62(Suppl. 1):S47-S63.
20. Bohlius J, Reiser M, Schwarzer G, et al. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haem 2003;122:413-423.
21. Gomez H, Mas L, Casanova L, et al. Elderly patients with aggressive non-Hodgkin 's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352-2358.
22. Schuster SJ, Venugopal P, Kern JC, et al. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk Lymphoma 2008;49:1681-1692.
23. Venugopal P, Sivaraman S, Preisler HD, et al. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res 2000;24:411-415.
24. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin 's lymphoma. J Clin Oncol 2001;19:389-397.
25. Vose JM, Link BK, Grossbard ML, et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggres sive non-Hodgkin 's lymphoma. Leuk Lymphoma 2005;46:1569-1573.
26. Coiffier B, Th ielblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemo therapy in DLBCL patients: a study by the Groupe d 'Etudes des Lymphomes de L 'Adulte. Blood 2010;116:2040-2045.
27. Gazitt Y, Shaughnessy P, Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin 's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001;10:177-186.
28. Morrissey PJ, Bressler L, Park LS, et al. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139:1113-1119.
29. Young DA, Lowe LD, Clark SC. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity. J Immunol 1990;145:607-615.
30. Eisenbeis CF, Grainger A, Fischer B, et al. Combination immunotherapy of B-cell non-Hodgkin 's lymphoma with rituximab and interleukin-2: a preclinical and phase study. Clin Cancer Res 2004;10:6101-6110.
31. Friedberg JW, Neuberg D, Gribben JG, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin 's lymphoma. Br J Haem 2002;117:828-834.
32. Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy. Br J Cancer 1995;71:655-659.
33. Younes A, Pro B, Robertson MJ, et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin 's lymphoma and Hodgkin 's disease. Clin Cancer Res 2004;10:5432-5438.
34. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Th er 2008;8:1295-1307.
35. Kimby E, Jurlander J, Geisler C, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008;49:102-112.
36. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000;95:999-1006.
37. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001;69:81-88.
38. Friedberg JW, Kim H, McCauley M, et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105:489-495.
39. Leonard JP, Link BK, Emmanouilides C, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin 's lymphoma. Clin Cancer Res 2007;13:6168-6174.
40. Friedberg JW, Kelly JL, Neuberg D, et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol 2009;146:282-291.
41. Chang JE, Seo S, Kim KM, et al. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin Lymphoma Myeloma Leuk 2010;10:379-384.
42. McLaughlin P, Liu N, Poindexter N, et al. Rituximab plus GMCSF (Leukine) for indolent lymphoma. Ann Oncol 2005;16(Suppl. 5): Abstract 104.
43. Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophase colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008;26:2725-2731.
44. Ferrajoli A, O 'Brien SM, Faderl SH, et al. The combination of rituximab and GMCSF in elderly patients with chronic lymphocytic leukemia (CLL). J Clin Oncol 2006;24(Suppl.): Abstract 6602.
45. Ferrajioli A. Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:514-516.
46. Rapoport AP, Meisenberg B, Sarkodee-Adoo C, et al. Autotransplantation for advanced lymphoma and Hodgkin 's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002;29:303-312.
47. Olivieri A, Lucesole M, Capelli D, et al. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 2005;11:627-636.
48. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496-502.
49. Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol 2007;25(18 Suppl.): Abstract 8009.
50. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin 's lymphoma. J Clin Oncol 2009;27(Suppl.): Abstract 8506.
51. Cunningham S, Muneer S, Aarati R, et al. The 51st Annual Meeting of the American Society of Hematology. Clinc Lymphoma Myeloma Leuk 2010;10:11-20.
52. Mikhaeel NG, Timothy AR, Hain SF, et al. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11(Suppl. 1):147-150.